Chimeric ubiquitin ligase capable of targeted degradation of KRAS, preparation method therefor and use thereof
By designing a chimeric ubiquitin ligase that targets the degradation of KRAS, combining KRAS binding domain and E3 ubiquitin ligase, the problem of difficult degradation of multiple mutant KRAS in the prior art is solved, and the multiple mutant KRAS is achieved effective degradation and widely applicable therapeutic effects.
Patent Information
- Application Number
- PCT/CN2023/099965
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-24
- Filing Date
- 2023-06-13
- Publication Date
- 2024-11-28
AI Technical Summary
The prior art is difficult to effectively degrade a variety of mutant KRAS proteins, resulting in a lack of universal applicability for targeted treatments against KRAS.
A chimeric ubiquitin ligase targeting the degradation of KRAS is designed, which combines the KRAS binding domain and E3 ubiquitin ligase, including RAF1, ARAF, PIP5K1A, RASSF2, APP and other proteins, and can bind to various mutant KRAS and Promote its degradation.
This chimeric ubiquitin ligase can effectively degrade different mutant KRAS, expand the scope of application of various cancers, and solve the problem that existing small molecule inhibitors have reduced binding ability due to the conformational changes of mutant KRAS.
Smart Images

Figure CN2023099965_28112024_PF_FP_ABST
Abstract
Description
Chimeric ubiquitin ligase for targeted degradation of KRAS and its preparation method and application Technical Field
[0001] The present invention belongs to the field of biomedicine, and specifically relates to a chimeric ubiquitin ligase for targeted degradation of KRAS, and a preparation method and application thereof. Background Art
[0002] RAS is a commonly mutated gene in tumors. In normal cells, RAS activation is in the downstream pathway of the cell membrane growth factor receptor family. RAS protein is a membrane-bound GTP / GDP-binding protein (GTPase). It is activated when bound to GTP and inactivated when bound to GDP. RAS isoforms are mainly encoded by three genes: KRAS, NRAS, and HRAS. KRAS is the most common mutant type in the RAS family and is associated with 22% of human tumors. It is a highly mutated gene in the three most lethal human cancers: lung cancer (17%), colorectal cancer (33%), and pancreatic cancer (61%). Common KRAS mutations mainly occur at codons 12, 13, 61, and 146 in exon 2, of which mutations occurring at sites 12 and 13 account for 90% of the total number of mutations.
[0003] Currently, the primary approach to inhibiting protein activity is to develop small-molecule inhibitors targeting the active sites of target proteins. However, research indicates that 85% of proteins, excluding KRAS, are considered "undruggable." These proteins are difficult to develop inhibitors for due to their loose and mutable structures, strong competition for binding with other small molecules within cells, and the susceptibility of active sites to mutation. Even though some small-molecule inhibitors targeting KRAS have been developed, their binding area with KRAS is too small. Even slight mutations and conformational changes in KRAS can affect the binding of the small-molecule inhibitors.
[0004] In addition, degrading protein accumulation in cells at the protein level is also an important strategy to reduce protein expression, among which protein degradation is an important method to reduce its accumulation in cells. The mainstream protein targeted degradation technology is to connect the target protein and E3 ligase together by constructing a chimeric molecule, thereby promoting the degradation of the target protein. The typical representative technology is PROTAC (protein degradation targeting chimera). It is reported that there are currently many proteins that can be rapidly degraded by PROTAC technology. However, in this technology, one PROTAC can only degrade one mutant KRAS, and cannot degrade multiple mutant KRAS, and is not universally applicable.
[0005] Summary of the Invention
[0006] The present invention aims to solve at least one of the technical problems existing in the above-mentioned prior art. To this end, the present invention provides a chimeric ubiquitin ligase that targets and degrades KRAS, which is capable of degrading different mutant KRAS.
[0007] The present invention also provides a nucleic acid molecule.
[0008] The present invention also provides a carrier.
[0009] The present invention also provides a host cell.
[0010] The present invention also provides a method for preparing the chimeric ubiquitin ligase that targets and degrades KRAS.
[0011] The present invention also proposes the use of the chimeric ubiquitin ligase for targeted degradation of KRAS in the preparation of products.
[0012] According to one aspect of the present invention, a chimeric ubiquitin ligase for targeted degradation of KRAS is provided, comprising a KRAS binding domain and an E3 ubiquitin ligase binding protein; the KRAS binding domain comprises at least one of RAF1(52-188), ARAF, PIP5K1A, RASSF2, APP, KRAS, and RAF1;
[0013] The amino acid sequence of RAF1(52-188) is:
[0014] or
[0015] An amino acid sequence shown in SEQ ID NO: 1 that has been modified by substitution, deletion, or addition of one or more amino acids and has the same or similar functions;
[0016] The amino acid sequence of the ARAF is:
[0017] SEQ ID NO:2: ASEPPRGPPANGAEPSRAVGTVKVYLPNKQRTVVTVRGMSVYDSLDKALKVRGLNQDCCVVYRLIKGRKTVTAWDTAIAPLDGEELIVEVLEDVPLTMHNFVRKTFFSLAFCDFCLKFLFHGFRCQTCGYKFHQHCSSKVPTVCVDMSTNRQQPSRFYHSVQDLSGGSRQHEAPSNRPLNELLTPQGPSP RTQHCDPEHFPFPAPANAPLQRIRSTSTPNVHMVSTTAPMDSNLIQLTGQSFSTDAAGSRGGSDGTPRGSPSPASVSSGRKSPHSKSPAEQRERKSLADDKKKVKNLGYRDSGYYWEVPPSEVQLLKRIGTGSFGTVFRGRWHGDVAVKVLKVSQPTAEQAQAFKNEMQVLRKTRHVNILLFMGFMTRPGFAIITQ WCEGSSLYHHLHVADTRFDMVQLIDVARQTAQGMDYLHAKNIIHRDLKSNNIFLHEGLTVKIGDFGLATVKTRWSGAQPLEQPSGSVLWMAAEVIRMQDPNPYSFQSDVYAYG OR
[0018] An amino acid sequence shown in SEQ ID NO: 2 that has been modified by substitution, deletion, or addition of one or more amino acids and has the same or similar functions;
[0019] The amino acid sequence of PIP5K1A is:
[0020] SEQ ID NO: 3: ; or
[0021] An amino acid sequence shown in SEQ ID NO: 3 that has been modified by substitution, deletion, or addition of one or more amino acids and has the same or similar functions;
[0022] The amino acid sequence of RASSF2 is:
[0023] SEQ ID NO:4:ASDYSHQTSLVPCGQDKYISKNELLLHLKTYNLYYEGQNLQLRHREEEDEFIVEGLLNISWGLRRPIRLQMQDDNERIRPPPSSSSWHSGCNLGAQGTTLKPLTVPKVQISEVDAPPEGDQMPSSTDSRGLKPLQEDTPQLMRTRSDVGVRRRGNVRTPSDQ or
[0024] An amino acid sequence shown in SEQ ID NO: 4 that has been modified by substitution, deletion, or addition of one or more amino acids and has the same or similar functions;
[0025] The amino acid sequence of the APP is:
[0026] SEQ ID NO:5:; or
[0027] An amino acid sequence shown in SEQ ID NO: 5 that has been modified by substitution, deletion, or addition of one or more amino acids and has the same or similar functions;
[0028] The amino acid sequence of KRAS is:
[0029] SEQ ID NO:6:ASTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFED IHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQGVDDAFYTLVREIRKHKEKMSKDGKKKKKKSKTKCVIMG; or
[0030] An amino acid sequence shown in SEQ ID NO: 6 that has been modified by substitution, deletion, or addition of one or more amino acids and has the same or similar functions;
[0031] The amino acid sequence of the RAF1 is:
[0032] SEQ ID NO:7:; or
[0033] The amino acid sequence shown in SEQ ID NO: 7 is modified by substitution, deletion or addition of one or more amino acids and has the same or similar functions.
[0034] According to a preferred embodiment of the present invention, there are at least the following beneficial effects:
[0035] In the chimeric ubiquitin ligase proposed by the present invention, all or part of the RAF1 protein, ARAF, PIP5K1A, RASSF2, APP, and KRAS protein can be used as natural binding proteins that specifically bind to activated KRAS. Among them, the RAF1 protein is a downstream protein of KRAS and only binds to activated KRAS, while mutant KRAS is basically in an activated state. This means that most mutant KRAS can bind to the RAF1 domain, that is, the chimeric ubiquitin ligase including the RAF1 domain can effectively degrade KRAS, solving the problem that the inhibitor (PROTAC) in the prior art reduces its ability to bind to KRAS due to KRAS mutations. In addition, due to the strong binding ability of the KRAS binding domain in the present invention to a variety of mutant KRAS, the chimeric ubiquitin ligase including the KRAS binding domain can effectively degrade different mutant KRAS, thereby being used to treat different cancers and having a wide range of applications.
[0036] In some embodiments of the present invention, the E3 ubiquitin ligase is selected from any one of the HECT domain family, RING domain family, and U.box domain family E3 ubiquitin ligases.
[0037] In some preferred embodiments of the present invention, the E3 ubiquitin ligase is selected from the RING domain family E3 ubiquitin ligase. Specifically, the E3 ubiquitin ligase is an adaptor protein / Cullin protein / E2 ubiquitin conjugate enzyme recruitment domain.
[0038] Specifically, the E3 ubiquitin ligase binding protein is part or all of the adaptor protein.
[0039] More specifically, the E3 ubiquitin ligase binding protein is part of the adaptor protein, and its amino acid sequence is:
[0040] a)SEQ ID NO:8:MGLDYKDDDDKASGSVNISGQNTMNMVKVPECRLADELGGLWENSRFTDCCLCVAGQEFQAHKAILAARSPPVFSAMFEHEMEESKKNRVEINDVEPEVFKEMMCFIYTGK APNLDKMADDLLAAADKYALERLKVMCEDALCSNLSVENAAEILILADLHSADQLKTQAVDFINYHASDVLETSGWKSMVVSHPHLVAEAYRSLASAQCPFLGPPRKRLKQSGS; or
[0041] b) An amino acid sequence shown in SEQ ID NO: 8 that has been modified by substitution, deletion or addition of one or more amino acids and has the same or similar functions.
[0042] In some embodiments of the present invention, the chimeric ubiquitin ligase further comprises a connexin, the amino acid sequence of which is shown in SEQ ID NO: 9: SGSGSG or SEQ ID NO: 10: SGSG.
[0043] In some embodiments of the present invention, the amino acid sequence of the chimeric ubiquitin ligase is:
[0044] a)SEQ ID NO:11:MGDYKDDDDKASSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSGSGSGSVNISGQNTMNMVKVPECRLADELGG OR
[0045] b) An amino acid sequence shown in SEQ ID NO: 11 that has been modified by substitution, deletion or addition of one or more amino acids and has the same or similar functions.
[0046] In some embodiments of the present invention, the amino acid sequence of the chimeric ubiquitin ligase composed of the ARAF and the E3 ubiquitin ligase binding protein is:
[0047] SEQ ID NO:12: MGDYKDDDDKASEPPRGPPANGAEPSRAVGTVKVYLPNKQRTVVTVRDGMSVYDSLDKALKVRGLNQDCCVVYRLIKGRKTVTAWDTAIAPLDGEELIVEVLEDVPLTMHNFVRKTFFSLAFCDFCLKFLFHGFRCQTCGYKFHQHCSSKVPTVCVDMSTNRQQPSRFYHSVQDLSGGSRQHEAPSNRPLNELLTPQGPSPRTQHCDPEHFPFPAPANAPLQRIRSTSTPNVHMVSTTAPMDSNLIQLTGQSFSTDAAGSRGGSDGTPRGSPSPASVSSGRKSPHSKSPAEQRERKSLADDKKKVKNLGYRDSGYYWEVPPSEVQLLKRIGTGSFGTVFRGRWHGDVAVKVLKVSQPTAEQAQAFKNEMQVLRKTRHVNILLFMGFMTRPGFAIITQWCEGSSLYHHLHVADTRFDMVQLIDVARQTAQGMDYLHAKNIIHRDLKSNNIFLHEGLTVKIGDFGLATVKTRWSGAQPLEQPSGSVLWMAAEVIRMQDPNPYSFQSDVYAYGVVLYELMTGSLPYSHIGCRDQIIFMVGRGYLSPDLSKISSNCPKAMRRLLSDCLKFQREERPLFPQILATIELLQRSLPKIERSASEPSLHRTQADELPACLLSAARLVPGSGSGSVNISGQNTMNMVKVPECRLADELGGLWENSRFTDCCLCVAGQEFQAHKAILAARSPVFSAMFEHEMEESKKNRVEINDVEPEVFKEMMCFIYTGKAPNLDKMADDLLAAADKYALERLKVMCEDALCSNLSVENAAEILILADLHSADQLKTQAVDFINYHASDVLETSGWKSMVVSHPHLVAEAYRSLASAQCPFLGPPRKRLKQSGS; or
[0048] An amino acid sequence which is the same as or similar in function to the amino acid shown in SEQ ID NO:12 after substitution, deletion or addition of one or more amino acids.
[0049] In some embodiments of the present invention, the amino acid sequence of the chimeric ubiquitin ligase composed of the PIP5K1A and the E3 ubiquitin ligase binding protein is:
[0050] SEQ ID NO:13:MGDYKDDDDKASASASSGPSSSVGFSSFDPAVPSCTLSSAASGIKRPMASEVLEARQDSYISLVPYASGMPIKKIGHRSVDSSGETTYKKTTSSALKGAIQLGITHTVGSLSTKPERDVLMQDFYVVESIFFPSEGSNLTPAHHYNDFRFKTYAPVAFRYFREL FGIRPDDYLYSLCSEPLIELCSSGASGSLFYVSSDDEFIIKTVQHKEAEFLQKLLPGYYMNLNQNPRTLLPKFYGLYCVQAGGKNIRIVVMNNLLPRSVKMHIKYDLKGSTYKRRASQKEREKPLPTFKDLDFLQDIPDGLFLDADMYNALCKTLQRDCLVLQSFKIMDY SLLMSIHNIDHAQREPLSSETQYSVDTRRPAPQKALYSTAMESIQGEARRGGTMETDDHMGGIPARNSKGERLLLYIGIIDILQSYRFVKKLEHSWKALVHDGDTVSVHRPGFY AERFQRFMCNTVFKKIPLKPSPSKKFRSGSSFSRRAGSSGNSCITYQPSVSGEHKAQVTTKAEVEPGVHLGRPDVLPQTPPLEEISEGSPIPDPSFSPLVGETLQMLTTSTTLE KLEVAESEFTHGSGSGSVNISGQNTMNMVKVPECRLADELGGLWENSRFTDCCLCVAGQEFQAHKAILAARSPVFSAMFEHEMEESKKNRVEINDVEPEVFKEMMCFIYTGKAP NLDKMADDLLAAADKYALERLKVMCEDALCSNLSVENAAEILILADLHSADQLKTQAVDFINYHASDVLETSGWKSMVVSHPHLVAEAYRSLASAQCPFLGPPRKRLKQSGS; or
[0051] An amino acid sequence having the same or similar function after one or more amino acids are substituted, deleted or added to the amino acid shown in SEQ ID NO: 13.
[0052] In some embodiments of the present invention, the amino acid sequence of the chimeric ubiquitin ligase composed of the RASSF2 and the E3 ubiquitin ligase binding protein is:
[0053] SEQ ID NO: 14: ; or
[0054] An amino acid sequence having the same or similar function after one or more amino acids are substituted, deleted or added to the amino acid shown in SEQ ID NO: 14.
[0055] In some embodiments of the present invention, the amino acid sequence of the chimeric ubiquitin ligase composed of the APP and the E3 ubiquitin ligase binding protein is:
[0056]
[0057] An amino acid sequence having the same or similar function after one or more amino acids are substituted, deleted or added to the amino acid shown in SEQ ID NO: 15.
[0058] In some embodiments of the present invention, the amino acid sequence of the chimeric ubiquitin ligase composed of the KRAS and the E3 ubiquitin ligase binding protein is:
[0059] SEQ ID NO:16:MGDYKDDDDKASTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDI HHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQGVDDAFYTLVREIRKHKEKMSKDGKKKKKKSKTKCVIMGSGSGSVNISGQNTM OR
[0060] An amino acid sequence having the same or similar function after one or more amino acids are substituted, deleted or added to the amino acid shown in SEQ ID NO: 16.
[0061] In some embodiments of the present invention, the amino acid sequence of the chimeric ubiquitin ligase composed of the RAF1 and the E3 ubiquitin ligase binding protein is:
[0062] SEQ ID NO:17: MGDYKDDDDKASEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVFGSGSGSVNISGQNTMNMVKVPECRLADELGGLWENSRFTDCCLCVAGQEFQAHKAILAARSPVFSAMFEHEMEESKKNRVEINDVEPEVFKEMMCFIYTGKAPNLDKMADDLLAAADKYALERLKVMCEDALCSNLSVENAAEILILADLHSADQLKTQAVDFINYHASDVLETSGWKSMVVSHPHLVAEAYRSLASAQCPFLGPPRKRLKQSGS; or
[0063] An amino acid sequence that is the same as or similar in function to the amino acid shown in SEQ ID NO:17 after substitution, deletion, or addition of one or more amino acids.
[0064] According to a second aspect of the present invention, a nucleic acid molecule is provided, comprising DNA or mRNA encoding the chimeric ubiquitin ligase targeting KRAS for degradation.
[0065] According to the third aspect of the present invention, a vector is provided, comprising the nucleic acid molecule.
[0066] In some embodiments of the present invention, the vector is an expression vector.
[0067] Specifically, the vector comprising the nucleic acid molecule can be used for cloning or for producing an expression vector, and the vector can be a plasmid, virus, phage or any other vector commonly used in genetic engineering.
[0068] Specifically, in addition to the nucleic acid molecule, the vector may also include eukaryotic or prokaryotic elements for controlling expression, such as regulatory sequences, enhancers, promoters, signal sequences, etc. for initiating and terminating transcription and / or translation.
[0069] In some embodiments of the invention, the vector comprises a bacterial, fungal, insect, viral or mammalian vector.
[0070] According to a fourth aspect of the present invention, a host cell is provided, comprising the nucleic acid molecule or the vector, wherein the host cell is a prokaryotic cell or a eukaryotic cell.
[0071] Specifically, the nucleic acid molecule or the vector can be introduced into a suitable host cell. The nucleic acid molecule can be introduced into the genome of the host cell; the vector can exist in the cytoplasm in an extrachromosomal form or be incorporated into the chromosome of the host cell.
[0072] In some embodiments of the invention, the prokaryotic cell is a bacterial cell.
[0073] In some embodiments of the present invention, the eukaryotic cell comprises a yeast cell, a filamentous fungal cell, a mammalian cell, or an insect cell.
[0074] According to a fifth aspect of the present invention, a method for preparing the chimeric ubiquitin ligase targeting KRAS degradation is provided, comprising the following steps: culturing the host cell of the fourth aspect to obtain the chimeric ubiquitin ligase.
[0075] According to a sixth aspect of the present invention, the use of the chimeric ubiquitin ligase for targeting KRAS degradation in the preparation of a product is provided. The product is any one of the following:
[0076] a) Agents that degrade KRAS protein;
[0077] b) Drugs for the treatment of KRAS-associated cancers.
[0078] In some embodiments of the present invention, the KRAS protein includes at least one of a wild-type KRAS protein and a mutant KRAS protein.
[0079] In some embodiments of the present invention, the mutant KRAS protein includes a KRAS protein mutated at at least one of the amino acid positions G12, G13, S17, P34, A59, Q61, and A146.
[0080] In some embodiments of the present invention, the KRAS-related cancer includes but is not limited to at least one of colorectal cancer, lung cancer, pancreatic cancer, liver cancer, and breast cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0081] The present invention will be further described below with reference to the accompanying drawings and embodiments, in which:
[0082] Figure 1 is a graph showing the Western blotting results of Example 2 of the present invention; wherein, C-blank control group, no transfection was performed; S1-control group, SPOP (167-374) was transfected; DS13(-)-transfected with DS13 expression vector, without MG132 (proteasome inhibitor); DS13(MG132)-transfected with DS13 expression vector, with MG132 added; RS14(-)-transfected with RS14 expression vector, without MG132 added; RS14(MG132)-transfected with RS14 expression vector, with MG132 added; Flag-tag indicates protein expression of S1, DS13, and RS14; HSP90-internal reference protein;
[0083] Figure 2 is a graph showing the Western blotting results of Example 3 of the present invention; wherein, C-blank control group, no transfection was performed; S1-control group, SPOP (167-374) was transfected; DS13(-)-transfected with DS13 expression vector without MG132; DS13(MG132)-transfected with DS13 expression vector with MG132 added; RS14(-)-transfected with RS14 expression vector without MG132 added; RS14(MG132)-transfected with RS14 expression vector with MG132 added; Flag-tag indicates protein expression of S1, DS13, and RS14; HSP90-internal reference protein;
[0084] Figure 3 is a graph showing the Western blotting results of Example 4 of the present invention; wherein, C-blank control group, no transfection was performed; S1-control group, SPOP (167-374) was transfected; DS13(-)-transfected with DS13 expression vector without MG132; DS13(MG132)-transfected with DS13 expression vector and MG132 was added; RS14(-)-transfected with RS14 expression vector without MG132; RS14(MG132)-transfected with RS14 expression vector and MG132 was added; Flag-tag indicates protein expression of S1, DS13, and RS14; HSP90-internal reference protein;
[0085] Figure 4 is a graph showing the Western blotting results of Example 5 of the present invention; wherein, C-blank control group, no transfection was performed; S1-control group, SPOP(167-374) was transfected; DS13(-)-transfected with DS13 expression vector without MG132; DS13(MG132)-transfected with DS13 expression vector and MG132 was added; RS14(-)-transfected with RS14 expression vector without MG132; RS14(MG132)-transfected with RS14 expression vector and MG132 was added; Flag-tag indicates protein expression of S1, DS13, and RS14; HSP90-internal reference protein. DETAILED DESCRIPTION
[0086] The embodiments of the present invention are described in detail below. The described embodiments are exemplary and are only used to explain the present invention, and are not to be construed as limiting the present invention.
[0087] In the description of the present invention, unless otherwise clearly defined, terms such as transfection and culture should be understood in a broad sense, and those skilled in the art can reasonably determine the specific meanings of the above terms in the present invention in combination with the specific content of the technical solution.
[0088] In the description of the present invention, reference to terms such as "one embodiment," "some embodiments," etc., means that a particular feature, material, or characteristic described in connection with that embodiment is included in at least one embodiment of the present invention. In this specification, schematic representations of such terms do not necessarily refer to the same embodiment. Furthermore, the particular features, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments.
[0089] Unless otherwise specified, the experimental methods used in the examples are conventional methods; the materials and reagents used are commercially available reagents and materials unless otherwise specified.
[0090] Example 1
[0091] In this example, a chimeric ubiquitin ligase RS14 was prepared to target and degrade KRAS. The specific process was as follows:
[0092] (1) The protein RAF1 that can bind to KRAS was searched from the PDB database, and the protein fragment RAF1 (52-188) that binds to KRAS was intercepted (amino acid sequence as shown in SEQ ID NO: 1: ASSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDW); RAF1 (52-188) was combined with the adaptor protein SPOP (167-374) (abbreviated as S1, which serves as an E3 ubiquitin ligase binding protein for binding to the Cullin protein in the E3 ubiquitin ligase (adapter protein / Cullin protein / E2 ubiquitin ligase recruitment domain);The amino acid sequence of which is shown in SEQ ID NO:8: MGLDYKDDDDKASGSVNISGQNTMNMVKVPECRLADELGGLWENSRFTDCCLCVAGQEFQAHKAILAARSPVFSAMFEHEMEESKKNRVEINDVEPEVFKEMMCFIYTGKAPNLDKMADDLLAAADKYALERLKVMCEDALCSNLSVENAAEILILADLHSADQLKTQAVDFINYHASDVLETSGWKSMVVSHPHLVAEAYRSLASAQCPFLGPPRKRLKQSGS) is connected in the middle by a linker protein (amino acid sequence shown in SEQ ID NO:9: SGSGSG) to form a chimeric ubiquitin ligase RS14 (amino acid sequence shown in SEQ ID NO: NO:11:MGDYKDDDDKASSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSGSGSGSVNISGQNTMNMVKVPECRLADELGGL WENSRFTDCCLCVAGQEFQAHKAILAARSPPVFSAMFEHEMEESKKNRVEINDVEPEVFKEMMCFIYTGKAPNLDKMADDLLAAADKYALERLKVMCEDALCSNLSVENAAEILILADLHSADQLKTQAVDFINYHASDVLETSGWKSMVVSHPHLVAEAYRSLASAQCPFLGPPRKRLKQSGS). ;
[0093] The corresponding mRNA sequence was deduced based on the amino acid sequence of the chimeric ubiquitin ligase RS14, as shown in SEQ ID NO:18: 5’-ATGGGCGACTACAAAGATGACGACGATAAAGCCTCCAGCAAGACCAGCAACACCATCAGAGTGTTCCTGCCTAACAAGCAGAGGACTGTGGTGAACGTGAGAAACGGCATGTCTCTGCATGACTGCCTGATGAAGGCCCTGAAGGTGAGAGGCCTGCAGCCCGAGTGCTGTGCCGTGTTCAGACTGCTGCACGAGCACAAGGGCAAGAAGGCCAGACTGGACTGGAACACCGATGCCGCCAGCCTGATCGGCGAGGAGCTGCAGGTGGATTTCCTGGACCATGTGCCTCTGACAACTCACAACTTTGCCCGGAAAACCTTTCTGAAGCTCGCATTCTGCGACATCTGCCAGAAGTTTCTGCTGAACGGGTTCAGGTGTCAGACCTGCGGCTATAAATTCCACGAGCACTGCTCTACCAAGGTGCCAACCATGTGTGTGGACTGGAGCGGCAGCGGATCTGGCAGCGTGAACATTAGTGGCCAGAACACCATGAATATGGTTAAAGTCCCAGAGTGCAGACTGGCCGACGAGCTGGGCGGCCTGTGGGAGAACTCTCGCTTCACCGACTGTTGCCTGTGCGTGGCCGGCCAGGAGTTCCAGGCCCACAAGGCCATTCTGGCCGCACGCAGCCCCGTGTTCTCCGCCATGTTTGAGCACGAGATGGAGGAGAGCAAGAAAAACCGGGTGGAAATCAACGATGTGGAACCTGAGGTGTTCAAGGAGATGATGTGCTTCATCTACACAGGCAAGGCCCCAAACCTCGACAAAATGGCCGACGACCTGCTGGCCGCCGCCGACAAATATGCTCTGGAAAGGCTGAAGGTGATGTGCGAGGATGCTCTGTGCAGTAATCTGAGCGTGGAGAACGCAGCCGAGATCCTGATTCTGGCCGACCTGCACAGCGCCGACCAGCTGAAGACCCAGGCCGTGGACTTTATCAACTATCATGCTTCAGACGTGCTGGAAACTAGTGGCTGGAAGAGCATGGTGGTTAGCCACCCACACCTGGTGGCTGAGGCCTATAGGTCCCTGGCCTCTGCTCAGTGCCCATTTCTGGGCCCTCCCCGGAAGAGACTGAAGCAGTCTGGAAGCTGA-3 'shown.This mRNA sequence is inserted in plasmid, forms RS14 expression vector.Use this RS14 expression vector to carry out following test.
[0094] Example 2
[0095] This example tests whether RS14 can knock down wild-type KRAS in HT29 cells (colon cancer cells). The specific process is as follows:
[0096] During the test, another chimeric ubiquitin ligase DS13 was also constructed for verification. In which, DS13 was obtained by connecting the protein DARPin.K27 that can bind to KRAS and SPOP (167-374) to obtain a chimeric ubiquitin ligase DS13 (its amino acid sequence is shown in SEQ ID NO:19:MGASGSDLGKKLLEAARAGQDDEVRILMANGADVNAHDTFGFTPLHLAALYGHLEIVEVLLKNGADVNADDSYGRTPLHLAAMRGHLEIVEVLLKYGADVNAADEEGRTPLHLAAKRGHLEIVEVLLKNGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLNGSGSGSGSVNISGQNTMNMVKVPECRLADE LGGLWENSRFTDCCLCVAGQEFQAHKAILAARSPVFSAMFEHEMEESKKNRVEINDVEPEVFKEMMCFIYTGKAPNLDKMADDLLAAADKYALERLKVMCEDALCSNLSVENAAEILILADLHSADQLKTQAVDFINYHASDVLETSGWKSMVVSHPHLVAEAYRSLASAQCPFLGPPRKRLKQSGSDYKDDDDKS). Its corresponding mRNA sequence such as SEQ ID NO: 20: 5'-ATGGGCGCCTCCGGAAGCGACCTCGGCAAGAAGCTGCTGGAGGCCGCCAGAGCCGGCCAGGACGATGAAGTGAGAATCCTGATGGCCAATGGAGCCGACGTGAACGCCCACGACACCTTCGGATTCACACCTCTGCACCTGGCCGCTCTGTACGGCCACCTGGAGATCGTGGAGGTGCTGCTGAAA AACGGCGCTGACGTGAATGCCGATGACAGCTACGGCAGAACACCCCTGCACCTCGCCGCCATGAGAGGGCACCTGGAGATTGTGGAGGTGCTGCTGAAGTACGGGGCCGACGTGAACGCCGCCGATGAAGAGGGAAGGACTCCACTGCACCTGGCCGCAAAGCGCGGGCACCTGGAAATCGTGGAGGTGCTGCTGAAs shown in 5'-AGAATGGGGCAGACGTGAACGCTCAGGACAAGTTCGGCAAAACAGCCTTCGACATCTCCATCGACAACGGCAACGAAGACCTGGCCGAAATCCTGCAGAAGCTGAATGGCAGCGGCAGCGGATCTGGCAGCGTGAACATTAGTGGCCAGAACACCATGAATATGGTTAAAGTCCCAGAGTGCAGACTGGCCGACGAGCTGGGCGGCCTGTGGGAGAACTCTCGCTTCACCGACTGTTGCCTGTGCGTGGCCGGCCAGGAGTTCCAGGCCCACAAGGCCATTCTGGCCGCACGCAGCCCCGTGTTCTCCGCCATGTTTGAGCACGAGATGGAGGAGAGCAAGAAAAACCGGGTGGAAATCAACGATGTGGAACCTGAGGTGTTCAAGGAGATGATGTGCTTCATCTACACAGGCAAGGCCCCAAACCTCGACAAAATGGCCGACGACCTGCTGGCCGCCGCCGACAAATATGCTCTGGAAAGGCTGAAGGTGATGTGCGAGGATGCTCTGTGCAGTAATCTGAGCGTGGAGAACGCAGCCGAGATCCTGATTCTGGCCGACCTGCACAGCGCCGACCAGCTGAAGACCCAGGCCGTGGACTTTATCAACTATCATGCTTCAGACGTGCTGGAAACTAGTGGCTGGAAGAGCATGGTGGTTAGCCACCCACACCTGGTGGCTGAGGCCTATAGGTCCCTGGCCTCTGCTCAGTGCCCATTTCTGGGCCCTCCCCGGAAGAGACTGAAGCAGTCTGGAAGCGACTACAAGGACGACGATGATAAGAGTTGA-3'. The mRNA sequence was inserted into a plasmid to form the DS13 expression vector, and the following experiments were carried out.
[0097] Seed 1×10 on a six-well plate 6HT29 cells were cultured in McCoy's 5A medium supplemented with 10% fetal bovine serum (FBS) and 1x penicillin / streptomycin and incubated in a 5% CO2, 37°C incubator. Overnight, the McCoy's 5A medium was replaced with 1 mL of OPTI medium. HT29 cells were then transfected with 2 μg of the S1, DS13, and RS14 expression vectors, respectively, using the commercial transfection reagent Lipofectamine MessengerMAX. Six hours after transfection, total protein was extracted for Western blotting analysis. The analysis results are shown in Figure 1. C represents the blank control group (untransfected); S1 represents the control group (transfected with SPOP(167-374); DS13(-) represents cells transfected with the DS13 expression vector without MG132 (a proteasome inhibitor); DS13(MG132) represents cells transfected with the DS13 expression vector with MG132 added; RS14(-) represents cells transfected with the RS14 expression vector without MG132; and RS14(MG132) represents cells transfected with the RS14 expression vector with MG132 added. Flag-tag indicates protein expression of S1, DS13, and RS14 (because S1, DS13, and RS14 all have Flag-tags); HSP90 serves as an internal control protein. As can be seen, DS13 significantly reduced the grayscale of the KRAS band compared to the control group, while RS14 had no significant effect. This indicates that DS13 can knock down wild-type KRAS, while RS14 has no significant knockdown effect on wild-type KRAS.
[0098] Example 3
[0099] This example tests whether RS14 can knock down the G12V mutant KRAS in SW480 cells (human colon cancer cells). The specific process is as follows:
[0100] 1×10 6SW480 cells were cultured in a cell culture medium (Leibovitz's L-15 supplemented with 10% FBS and 1× penicillin / streptomycin) and cultured in a 5% CO2, 37°C incubator. After overnight, the Leibovitz's L-15 culture medium was replaced with 1 mL of OPTI culture medium, and 2 μg of S1, DS13 expression vectors, and RS14 expression vectors were transfected into SW480 cells using the commercial transfection reagent Lipofectamine MessengerMAX. 6 hours after transfection, total cell protein was extracted for Western blotting analysis. The analysis results are shown in Figure 2, and the specific labeling is the same as in Example 2. It can be seen that compared with the control group, RS14 can significantly reduce the grayscale of the KRAS band, while the reduction effect of DS13 is not obvious. This shows that RS14 can knock down the G12V mutant KRAS, while DS13 has no obvious knockdown effect on the G12V mutant KRAS.
[0101] Example 4
[0102] This example tested whether RS14 could knock down the G12S mutant KRAS in A549 cells (human non-small cell lung cancer cells). The specific process was as follows:
[0103] 1×10 6 A549 cells were cultured in a cell culture medium (Ham's F-12K supplemented with 10% FBS and 1× penicillin / streptomycin) and cultured in a 5% CO2, 37°C incubator. After overnight, the Ham's F-12K culture medium was replaced with 1 mL of OPTI culture medium, and 2 μg of S1, DS13 expression vectors, and RS14 expression vectors were transfected into A549 cells using the commercial transfection reagent Lipofectamine MessengerMAX. 6 hours after transfection, total cell protein was extracted for Western blotting analysis. The analysis results are shown in Figure 3, and the specific labeling is the same as in Example 2. It can be seen that compared with the control group, RS14 can significantly reduce the grayscale of the KRAS band, while the reduction effect of DS13 is not obvious. This shows that RS14 can knock down the G12S mutant KRAS, while DS13 has no obvious knockdown effect on the G12S mutant KRAS.
[0104] Example 5
[0105] This example tested whether RS14 could knock down the G12D mutant KRAS in PANC1 cells (human pancreatic cancer cells). The specific process was as follows:
[0106] 1×10 6PANC1 cells were cultured in a cell culture medium (DMEM supplemented with 10% FBS and 1× penicillin / streptomycin) and placed in a 5% CO2, 37°C incubator. After overnight, the DMEM culture medium was replaced with 1 mL of OPTI culture medium, and 2 μg of S1, DS13 expression vectors, and RS14 expression vectors were transfected into PANC1 cells using the commercial transfection reagent Lipofectamine MessengerMAX. 6 hours after transfection, total cell protein was extracted for Western blotting analysis. The analysis results are shown in Figure 4, and the specific labeling is the same as in Example 2. It can be seen that compared with the control group, the effect of RS14 on reducing the grayscale of the KRAS band is more obvious than that of DS13. This shows that RS14 can knock down the G12D mutant KRAS.
[0107] It can be seen from the above examples that RS14 can degrade various mutant KRAS but not wild-type KRAS, which may be because RAF1 protein is more likely to bind to activated KRAS (ie, mutant KRAS).
[0108] While the embodiments of the present invention have been described in detail above, the present invention is not limited to the embodiments described above. Various modifications may be made within the scope of knowledge possessed by a person skilled in the art without departing from the spirit of the present invention. Furthermore, the embodiments of the present invention and the features thereof may be combined with one another unless there is a conflict.
Claims
1. A chimeric ubiquitin ligase targeting KRAS degradation, characterized in that: It includes a KRAS binding domain and an E3 ubiquitin ligase binding protein; the KRAS binding domain includes at least one of RAF1 (52-188), ARAF, PIP5K1A, RASSF2, APP, KRAS, and RAF1; The amino acid sequence of RAF1 (52-188) is: SEQ ID NO: 1; or an amino acid sequence of SEQ ID NO: 1 which has one or more amino acids substituted, deleted or added and has the same or similar functions; The amino acid sequence of ARAF is: SEQ ID NO: 2; or an amino acid sequence of SEQ ID NO: 2 that is modified by substitution, deletion or addition of one or more amino acids and has the same or similar functions; The amino acid sequence of PIP5K1A is: SEQ ID NO: 3; or an amino acid sequence shown in SEQ ID NO: 3 which is modified by substitution, deletion or addition of one or more amino acids and has the same or similar functions; The amino acid sequence of RASSF2 is: SEQ ID NO: 4; or an amino acid sequence shown in SEQ ID NO: 4 which is modified by substitution, deletion or addition of one or more amino acids and has the same or similar functions; The amino acid sequence of the APP is: SEQ ID NO: 5; or an amino acid sequence shown in SEQ ID NO: 5 which is modified by substitution, deletion or addition of one or more amino acids and has the same or similar functions; The amino acid sequence of KRAS is: SEQ ID NO: 6; or an amino acid sequence of SEQ ID NO: 6 that is modified by substitution, deletion or addition of one or more amino acids and has the same or similar functions; The amino acid sequence of RAF1 is: SEQ ID NO: 7; or an amino acid sequence shown in SEQ ID NO: 7 which is modified by substitution, deletion or addition of one or more amino acids and has the same or similar functions.
2. The chimeric ubiquitin ligase according to claim 1, characterized in that The amino acid sequence of the E3 ubiquitin ligase binding protein is: SEQ ID NO: 8; or an amino acid sequence shown in SEQ ID NO: 8 which has been modified by substitution, deletion or addition of one or more amino acids and has the same or similar functions.
3. The chimeric ubiquitin ligase according to claim 2, characterized in that The amino acid sequence of the chimeric ubiquitin ligase is: a)SEQ ID NO:11:MGDYKDDDDKASSKTSNTIRVFLPNKQRTVVNVRNGMSLH DCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSGSGSGSVNISGQNTMNMVKVPECRLADELGGLWENSRFTDCCLCVAGQEFQAHK OR b) An amino acid sequence shown in SEQ ID NO: 11 which has been modified by substitution, deletion or addition of one or more amino acids and has the same or similar functions.
4. A nucleic acid molecule, characterized in that The nucleic acid molecule comprises a DNA or mRNA encoding the chimeric ubiquitin ligase according to any one of claims 1 to 3.
5. A carrier, characterized in that The vector comprises the nucleic acid molecule of claim 4.
6. The carrier according to claim 5, characterized in that The vectors include bacterial, fungal, insect, viral or mammalian vectors.
7. A host cell, characterized in that The host cell comprises the nucleic acid molecule according to claim 4 or the vector according to any one of claims 5 to 6, and the host cell is a prokaryotic cell or a eukaryotic cell.
8. The method for preparing the chimeric ubiquitin ligase according to any one of claims 1 to 3, characterized in that: The method comprises the following steps: culturing the host cell according to claim 7 to obtain the chimeric ubiquitin ligase.
9. Use of the chimeric ubiquitin ligase according to any one of claims 1 to 3 in preparing a product, characterized in that: The product is any of the following: a) Agents that degrade KRAS protein; b) Drugs for the treatment of KRAS-associated cancers.
10. The use according to claim 9, characterized in that: The KRAS protein includes at least one of a wild-type KRAS protein and a mutant KRAS protein; Preferably, the mutant KRAS protein includes a KRAS protein mutated at at least one amino acid position of G12, G13, S17, P34, A59, Q61, and A146.
Citation Information
Patent Citations
Degradation of surface proteins using bispecific binding agents
CN114867752A
Chimeric vector and preparation method and use thereof
WO2015192339A1
Chimaeric proteins and therapeutic agents
WO2021229221A2
Fusion proteins comprising an e2 ubiquitin or ubiquitin-like conjugating domain and a targeting domain for specific protein degradation
WO2022106869A1
